Complicated Urinary Tract Infection Treatment Market Report 2026

The complicated urinary tract infection treatment market size has grown strongly in recent years. It will grow from $9.44 billion in 2025 to $10.04 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing prevalence of catheter associated infections, rising antibiotic resistance, growth in aging population, expanding hospital infrastructure, higher diagnosis of chronic urinary disorders.

The complicated urinary tract infection treatment market size is expected to see strong growth in the next few years. It will grow to $12.74 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to development of novel antibiotics, growth in immunocompromised patient base, increasing use of outpatient infusion therapies, rising healthcare expenditure, improved pathogen identification technologies. Major trends in the forecast period include empiric therapy optimization, rising use of broad spectrum antibiotics, increased hospitalization for complicated UTIs, growing preference for combination drug therapies, expansion of hospital pharmacy based dispensing.

The rising incidence of chronic kidney disease is expected to drive the growth of the complicated urinary tract infection treatment market in the coming years. Chronic kidney disease is a long-term condition marked by a gradual decline in kidney function over time. The increasing occurrence of chronic kidney disease is largely attributed to higher rates of diabetes and hypertension, along with aging populations and lifestyle-related factors such as obesity and smoking. Treatment for complicated urinary tract infections plays an important role for patients with chronic kidney disease by preventing severe infections, including pyelonephritis, that can aggravate kidney damage, further impair renal function, and accelerate disease progression, thereby lowering the risk of additional complications and hospital admissions. For example, in June 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, chronic kidney disease accounted for 1.1% of the total disease burden in Australia in 2023. Therefore, the increasing prevalence of chronic kidney disease is contributing to the growth of the complicated urinary tract infection treatment market.

Major companies operating in the complicated urinary tract infection treatment market are increasingly focused on addressing antibiotic resistance through the development of novel antibiotics to improve treatment effectiveness and combat emerging multidrug-resistant pathogens. Anti-infective therapies for complicated urinary tract infections involve the use of targeted antibiotics or antimicrobial agents to control or eliminate infections, particularly in severe cases with kidney involvement. For instance, in February 2024, Allecra Therapeutics, a Germany-based biopharmaceutical company, announced approval from the US Food and Drug Administration for EXBLIFEP (cefepime and enmetazobactam) for the treatment of complicated urinary tract infections in adults. The company also received a five-year marketing exclusivity extension under the GAIN Act, which encourages the development of new anti-infective therapies. Clinical data showed that 79.1% of patients treated with cefepime and enmetazobactam achieved a composite response of clinical cure and microbiological eradication, compared with 58.9% of patients treated with piperacillin and tazobactam.

In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, partnered with Cipla Limited to launch the antibiotic cefepime enmetazobactam in India. Through this collaboration, the companies aim to use Cipla’s established distribution network to increase access to cefepime enmetazobactam, an antibiotic indicated for the treatment of complicated urinary tract infections, including pyelonephritis. Cipla Limited is an India-based pharmaceutical company focused on developing and delivering effective treatments for complicated urinary tract infections through advanced antibiotic therapies and innovative healthcare solutions.

Major companies operating in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.

North America was the largest region in the complicated urinary tract infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complicated urinary tract infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the complicated urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created cost and supply chain pressures in the complicated urinary tract infection treatment market by increasing the prices of active pharmaceutical ingredients, injectable antibiotics, and formulation chemicals sourced from international suppliers. These tariffs have particularly affected cephalosporins, quinolones, and antifungal drug segments, with Asia-Pacific and European manufacturing hubs being the most impacted due to their heavy reliance on cross-border pharmaceutical trade. Hospital pharmacies and specialty urology clinics have experienced higher procurement costs, leading to price adjustments and delayed inventory replenishment. However, tariffs have also encouraged domestic pharmaceutical manufacturing, increased local production of antibiotics, and supported regional supply chain resilience across key healthcare markets.

The complicated urinary tract infection treatment market research report is one of a series of new reports that provides complicated urinary tract infection treatment market statistics, including complicated urinary tract infection treatment industry global market size, regional shares, competitors with a complicated urinary tract infection treatment market share, detailed complicated urinary tract infection treatment market segments, market trends and opportunities, and any further data you may need to thrive in the complicated urinary tract infection treatment industry. This complicated urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Complicated urinary tract infection treatment refers to the clinical management of urinary tract infections that occur in patients with underlying conditions that increase the risk of poor treatment outcomes. This type of treatment involves the use of targeted antibiotics and supportive therapies to address infections caused by resistant organisms or conditions that hinder recovery. It is used to manage severe urinary tract infections in individuals with structural abnormalities of the urinary tract, compromised immune systems, or catheter use, helping ensure effective infection control and preventing further complications.

The primary drug types used in the treatment of complicated urinary tract infections include penicillin and combination therapies, quinolones, cephalosporins, azoles and amphotericin B, and nitrofurans. Penicillin and combination therapies consist of antibiotics derived from penicillin that are often paired with beta-lactamase inhibitors to improve activity against resistant bacteria. These treatments are distributed through multiple channels such as hospital pharmacies, gynecology and urology clinics, and drug stores, and are used to treat conditions including urethritis, cystitis, and pyelonephritis.

The complicated urinary tract infection treatment market consists of sales of antibiotics, antifungals, and combination therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.